ALLIANCE (clinical trials group)

ALLIANCE (clinical trials group)
Name	ALLIANCE
Caption	Alliance for Clinical Trials in Oncology logo
Formation	2014
Predecessor	Cancer and Leukemia Group B; North Central Cancer Treatment Group; American College of Surgeons Oncology Group
Type	Clinical trials cooperative group
Headquarters	Bethesda, Maryland
Leader title	Executive Officer
Leader name	Richard L. Schilsky

ALLIANCE (clinical trials group) is a United States-based cooperative group that designs, conducts, and analyzes multicenter oncology clinical trials. The group formed from a consolidation of legacy cooperative groups to streamline trials for National Cancer Institute-sponsored oncology research involving investigators from academic centers such as Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center, Johns Hopkins Hospital and community sites affiliated with Mayo Clinic, Cleveland Clinic, and MD Anderson Cancer Center. ALLIANCE protocols influence practice at institutions including Massachusetts General Hospital, Fred Hutchinson Cancer Center, Stanford Health Care, and international partners such as University College London and Princess Margaret Cancer Centre.

History and formation

ALLIANCE emerged from the merger of the Cancer and Leukemia Group B, North Central Cancer Treatment Group, and the American College of Surgeons Oncology Group as part of National Cancer Institute cooperative group restructuring under the National Institutes of Health. Founding leaders included physicians and investigators from University of Chicago, University of Minnesota, University of Wisconsin–Madison, University of Pennsylvania, and Duke University School of Medicine. The consolidation paralleled initiatives seen in organizations like European Organisation for Research and Treatment of Cancer and Cancer Research UK consortia to increase trial efficiency. Early strategic planning involved stakeholders from American Society of Clinical Oncology, American Association for Cancer Research, Society of Surgical Oncology, and patient advocacy groups such as Susan G. Komen.

Organization and governance

Governance follows a committee structure with an Executive Committee, Disease Steering Committees, and a Scientific Review Board, drawing members from institutions like Columbia University Vagelos College of Physicians and Surgeons, Yale School of Medicine, Northwestern University Feinberg School of Medicine, and University of California, San Francisco. Regulatory oversight interfaces with the Food and Drug Administration and the Office for Human Research Protections, while data management collaborates with the Alliance Statistics and Data Center and networks including SWOG and ECOG-ACRIN. Leadership appointments have been held by oncology researchers affiliated with University of Pittsburgh Medical Center, Vanderbilt University Medical Center, and University of Texas Southwestern Medical Center.

Research programs and trial portfolio

ALLIANCE maintains programs across disease sites including breast cancer, lung cancer, gastrointestinal malignancies, genitourinary cancers, leukemia, lymphoma, and sarcoma, involving laboratories at Fred Hutchinson Cancer Center, Sloan Kettering Institute, Broad Institute, and Dana-Farber. Translational science efforts link with programs at Cold Spring Harbor Laboratory, Salk Institute, Scripps Research, and genomic initiatives akin to The Cancer Genome Atlas and International Cancer Genome Consortium. Trials incorporate targeted therapies developed by pharmaceutical partners such as Roche, Pfizer, Novartis, Bristol Myers Squibb, and device collaborations with Medtronic and Siemens Healthineers.

Major clinical trials and findings

Key randomized trials addressed adjuvant therapy in breast cancer paralleling outcomes from studies at Royal Marsden Hospital and chemotherapy scheduling evidence similar to work from Institut Gustave Roussy. Lung cancer trials evaluated immunotherapy regimens reflecting advances from Memorial Sloan Kettering Cancer Center and Vanderbilt-Ingram Cancer Center, while colorectal cancer protocols produced data influential alongside trials from MD Anderson and Mayo Clinic Cancer Center. Hematologic oncology trials incorporated stem cell transplant strategies comparable to protocols at Fred Hutchinson Cancer Center and City of Hope. Results have been cited in guideline revisions by National Comprehensive Cancer Network, American Society of Clinical Oncology, and regulatory decisions by the Food and Drug Administration.

Collaborations and partnerships

ALLIANCE partners with cooperative groups such as SWOG, ECOG-ACRIN, and international groups including European Society for Medical Oncology affiliates, and networks like NCI Community Oncology Research Program. Academic collaborations include Harvard Medical School, Imperial College London, McGill University Health Centre, and industry partnerships with companies including AstraZeneca and Merck & Co.. Engagements extend to registries and consortia such as SEER Program, ClinicalTrials.gov registrants, and initiatives with philanthropic organizations like Bill & Melinda Gates Foundation and disease-focused charities exemplified by Leukemia & Lymphoma Society.

Funding and infrastructure

Primary funding sources include the National Cancer Institute cooperative group grant mechanisms, supplemental support from institutes like National Institute of Allergy and Infectious Diseases for correlative science, and sponsored research agreements with biotechnology firms such as Genentech and Amgen. Infrastructure leverages data centers and biorepositories at centers like University of Michigan Rogel Cancer Center, University of North Carolina Lineberger Comprehensive Cancer Center, and Indiana University Melvin and Bren Simon Cancer Center, with laboratory support from Vanderbilt-Ingram Cancer Center core facilities and bioinformatics collaborations with Johns Hopkins Bloomberg School of Public Health.

Impact on oncology practice and guidelines

ALLIANCE trial results have influenced clinical practice and guideline updates by NCCN, ASCO, and specialty societies including American Society of Hematology and Society of Gynecologic Oncology, informing standards at major centers such as Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, and UCLA Health. Its translational findings have been integrated into molecular testing recommendations promoted by College of American Pathologists and consensus statements from organizations like European Society for Medical Oncology, shaping treatment pathways used at institutions including Penn Medicine and Cedars-Sinai Medical Center.

Category:Clinical trials